Background Emerging evidence supports the health benefits of ginger for a range of conditions and symptoms; however, there is a lack of synthesis of literature to determine which health indications are supported by quality evidence. Objectives This umbrella review of systematic reviews aimed to determine the therapeutic effects and safety of any type of ginger from the Zingiber family administered in oral form compared with any comparator or baseline measures on any health and wellbeing outcome in humans. Design Five databases were searched to April 2021. Review selection and quality was assessed in duplicate using the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) Checklist and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method, with results presented narratively. Results Twenty-four systematic reviews were included with 3% overlap of primary studies. Strongest evidence was found for the antiemetic effects of ginger in pregnant women (effect size: large; GRADE: high), analgesic effects for osteoarthritis (effect size: small; GRADE: high), and glycemic control (effect size: none-to-very large; GRADE: very low-to-moderate). Ginger also had a statistically significant positive effect on blood pressure, weight management, dysmenorrhea, post-operative nausea, and chemotherapy-induced vomiting (effect size: moderate-to-large; GRADE: low-to-moderate) as well as blood lipid profile (effect size: small; GRADE: very low) and anti-inflammatory and antioxidant biomarkers (effect size: unclear; GRADE: very low-to-moderate). There was substantial heterogeneity and poor reporting of interventions; however, doses of 0.5–3 g per day in capsule form administered for up to three months was consistently reported as effective. Conclusions Dietary consumption of ginger appears safe and may exert beneficial effects on human health and wellbeing, with greatest confidence in antiemetic effects in pregnant women, analgesic effects in osteoarthritis, and glycemic control. Future randomized controlled and dose-dependent trials with adequate sample sizes and standardized ginger products are warranted to better inform and standardize routine clinical prescription. Registration: International Prospective Register of Systematic Reviews (PROSPERO) ID: CRD42020197925.